Compare PFX & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFX | STIM |
|---|---|---|
| Founded | 2010 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.7M | 105.5M |
| IPO Year | N/A | 2018 |
| Metric | PFX | STIM |
|---|---|---|
| Price | $44.56 | $2.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 1.5K | ★ 1.4M |
| Earning Date | 02-06-2026 | 03-03-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.06 | N/A |
| Revenue | $25,262,322.00 | ★ $129,873,000.00 |
| Revenue This Year | N/A | $101.67 |
| Revenue Next Year | N/A | $10.87 |
| P/E Ratio | $20.61 | ★ N/A |
| Revenue Growth | 13.89 | ★ 78.61 |
| 52 Week Low | $41.00 | $1.25 |
| 52 Week High | $57.40 | $5.92 |
| Indicator | PFX | STIM |
|---|---|---|
| Relative Strength Index (RSI) | 53.15 | 61.96 |
| Support Level | $42.88 | $2.05 |
| Resistance Level | $43.75 | $2.29 |
| Average True Range (ATR) | 0.66 | 0.20 |
| MACD | -0.06 | 0.04 |
| Stochastic Oscillator | 53.78 | 70.94 |
PhenixFIN Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.